自适应计划同步化质子治疗不可切除III期非小细胞肺癌的2期研究
这项2期研究前瞻性评估了同步化质子治疗(CCPT)联合自适应计划治疗不可切除III期非小细胞肺癌的疗效与安全性,主要终点为总生存(OS)。
要点
- 2年和5年OS分别为77%和59%,中位OS未达到。
- 未观察到3级及以上放射性肺炎,24个月后除脱发外生活质量无显著恶化。
核心结论
- 自适应计划同步化质子治疗耐受性良好,在不可切除III期NSCLC中取得了显著的OS。
研究设计与样本
- 主要终点为OS,次要终点包括局部控制率(LCR)、无进展生存(PFS)、3级及以上不良事件发生率和生活质量(QOL)变化。
- 患者接受顺铂(60 mg/m2)第1天和S-1(约40 mg/m2,每日两次)第1-14天,每4周重复,最多4周期,同步质子治疗原发灶总剂量70 GyRBE、淋巴结转移66 GyRBE,每日2 GyRBE。
- 质子治疗采用呼吸门控和图像引导技术,并实施自适应计划。
主要发现
- 34例患者完成4周期顺铂联合S-1化疗,平均周期数为4(范围1-4)。
- 全部患者和存活患者的中位随访时间分别为37个月(范围4-84)和52个月(范围26-84)。
- 平均再计划次数为2.5次(范围1-4)。
- 2年和5年OS分别为77%(95%CI 64%-89%)和59%(95%CI 43%-76%)。
- 2年和5年LCR分别为84%(95%CI 73%-95%)和61%(95%CI 44%-78%),PFS分别为43%(95%CI 28%-57%)和37%(95%CI 22%-51%)。
关键数值与推荐
- 质子治疗剂量:原发灶70 GyRBE,淋巴结转移66 GyRBE,每日2 GyRBE。
- 化疗方案:顺铂60 mg/m2第1天,S-1约40 mg/m2每日两次第1-14天,每4周重复,最多4周期。
临床怎么用
- 对于不可切除III期NSCLC,可考虑同步化质子治疗联合自适应计划,需配合呼吸门控和图像引导技术。
- 治疗过程中平均需2.5次再计划,应建立自适应计划流程以保证靶区覆盖和正常组织保护。
局限性
- 中位OS未达到,长期生存数据仍需更长时间随访。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: This study prospectively evaluated the efficacy and safety of concurrent chemo-proton therapy (CCPT) using adaptive planning for unresectable stage III non-small cell lung cancer (NSCLC). METHODS AND MATERIALS: The primary endpoint was overall survival (OS). Secondary endpoints were local control rate (LCR), progression-free survival (PFS), incidence of grade 3 or higher adverse events, and changes in quality of life (QOL). Patients received cisplatin (60 mg/m2) on day 1 and S-1 (∼40 mg/m2 twice daily) on days 1 to 14, q4w, for up to 4 cycles, plus concurrent proton therapy at a total dose of 70 GyRBE for the primary lesion and 66 GyRBE for lymph node metastasis with 2 GyRBE per day. Proton therapy was performed using respiratory-gated and image guided techniques, and adaptive plans were implemented. RESULTS: Forty-seven patients were enrolled between August 2013 and August 2018. Four cycles of cisplatin plus S-1 were completed in 34 patients. The mean number of cycles was 4 (range, 1-4). The median follow-up of all and surviving patients was 37 (range, 4-84) and 52 months (range, 26-84), respectively. The mean number of replanning sessions was 2.5 (range, 1-4). The 2- and 5-year OS, LCR, and PFS were 77% (95% confidence interval 64%-89%) and 59% (43%-76%), 84% (73%-95%) and 61% (44%-78%), and 43% (28%-57%) and 37% (22%-51%), respectively. The median OS was not reached. No grade 3 or higher radiation pneumonitis was observed. There was no significant deterioration in the QOL scores after 24 months except for alopecia. CONCLUSIONS: CCPT with adaptive planning was well tolerated and yielded remarkable OS for unresectable stage III NSCLC.
引用
- Iwata H, Akita K, Yamaba Y, et al. Concurrent Chemo-Proton Therapy Using Adaptive Planning for Unresectable Stage 3 Non-Small Cell Lung Cancer: A Phase 2 Study. Int J Radiat Oncol Biol Phys. 2020. PMID: 33227444. doi:10.1016/j.ijrobp.2020.11.035
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。